• 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Thoracic cancer. >Prognostic value of quantitative measurement of EGFR mutation using peptide nucleic acid clamping in advanced EGFR mutant non‐small cell lung cancer patients
【24h】

Prognostic value of quantitative measurement of EGFR mutation using peptide nucleic acid clamping in advanced EGFR mutant non‐small cell lung cancer patients

机译：先进EGFR突变体非小细胞肺癌患者肽核酸夹持肽核酸定量测量的预后值

获取原文
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

The presence of EGFR mutation in patients with advanced non-small cell lung cancer (NSCLC) plays an important role in determining the appropriate treatment, response, and survival. Therefore, this study attempted to predict the prognosis of NSCLC patients using data from quantitative mutation measurements. The data of patients with advanced NSCLC who underwent EGFR mutation testing using the peptide nucleic acid (PNA) mediated clamping method at the Pusan National University Hospital from October 2015 to December 2017 were retrospectively analyzed. The efficiency of PNA clamping was determined by measuring the threshold cycle (Ct ) value. The ΔCt -1 value (standard Ct value minus sample Ct value) was calculated to quantify EGFR mutation. During the study period, 71 patients were treated with EGFR-tyrosine kinase inhibitors. The cutoff point for the ΔCt -1 value derived from the receiver operating characteristic curve was 5.32. A survival benefit was observed in the group with an ΔCt 5.32 or with a common EGFR mutation type compared to the group with an ΔCt -1 value 5.32. EGFR mutation testing using PNA clamping may predict patient survival, especially in patients with common EGFR mutations, such as exon 19 deletion or L858R. A higher ΔCt -1 value correlates with better survival. ? 2019 The Authors. Thoracic Cancer published by China Lung Oncology Group and John Wiley & Sons Australia, Ltd.
机译：晚期非小细胞肺癌（NSCLC）患者EGFR突变的存在在确定适当的治疗，反应和存活方面发挥着重要作用。因此，本研究试图预测使用来自定量突变测量的数据的NSCLC患者的预后。回顾性分析了2015年10月至2017年12月，在蒲公英核酸（PCNA）介导的突变突变检测接受EGFR突变试验的先进NSCLC患者的数据。通过测量阈值循环（CT）值来确定PNA钳位的效率。计算ΔCt-1值（标准CT值减去样品CT值）以量化EGFR突变。在研究期间，用EGFR-酪氨酸激酶抑制剂治疗71名患者。从接收器操作特性曲线导出的ΔCt-1值的截止点为5.32。与具有ΔCt-1值<5.32的基团相比，在具有ΔCT5.32或常见的EGFR突变型中观察到存活益处。使用PNA夹紧的EGFR突变测试可以预测患者存活，特别是在常见EGFR突变的患者中，例如外显子19缺失或L858R。更高的ΔCt-1值与更好的存活率相关。 ？ 2019年的作者。中国肺部肿瘤集团和约翰瓦里和儿子澳大利亚发表的胸癌

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号